Relation among Perceived Weight Change, Sedentary Activities and Sleep Quality during COVID-19 Lockdown: A Study in an Academic Community in Northern Italy

In Italy, COVID-19 lockdown was imposed from 8 March until 3 May 2020 with negative consequences on the lifestyles and health of people. Within this context, the paper aims: (i) to analyse the impact of COVID-19 lockdown on perceived weight changes; (ii) to evaluate factors associated with the perception of weight changes (Body Mass Index (BMI), sleep quality, time spent in sedentary activities), in an Italian academic community of students and workers. A total of 3666 participants took part in this cross-sectional study (2838 students and 828 workers, of whom 73.0% were female). T-test, Chi-square test and the two-way ANOVA were used. Results showed that 43.3% of participants perceived a weight gain. Workers experienced a more substantial increase in body weight (0.7 kg) compared to students (0.3 kg; p = 0.013). A significant difference between preobese/obese workers (0.9 kg) and students (−0.3 kg; p < 0.001) was found. Overall, 57.0% of the sample was characterized by high levels of sedentary activities. Sedentary people noticed a higher weight gain (0.4 kg) compared to less sedentary people (0.3 kg; p = 0.048). More than 45% of participants reported a worsening of sleep quality and showed a perceived increase in body weight (0.5 kg) in comparison to those who improved their sleep quality (no weight change; p = 0.001). Designing tailored interventions to promote health-related behaviours during lockdown periods is essential.

Download Full-text

Effects of Different Integrase Inhibitors on Body Weight in Patients with HIV/AIDS: A Network Meta-Analysis

10.21203/rs.3.rs-136545/v1 ◽

2020 ◽

Author(s):

Ruojing Bai ◽

Shiyun Lv ◽

Hao Wu ◽

Lili Dai

Keyword(s):

Body Weight ◽

Weight Gain ◽

Meta Analysis ◽

Biomedical Literature ◽

Cochrane Library ◽

Weight Changes ◽

Aids Patients ◽

First Choice ◽

Significant Difference ◽

Hiv Aids

Abstract Background: Global antiretroviral therapy has entered the era of integrase strand transfer inhibitor (INSTI). Because INSTIs have the advantages of high antiviral efficacy, rapid virus inhibition, and good tolerance, they have become the first choice in international acquired immunodeficiency syndrome (AIDS) treatment guidelines. However, they may also increase the risk of obesity. There are differences in the effects of different INSTIs on weight gain in Human immunodeficiency virus (HIV) infection / AIDS patients, but there is no evidence-based medical evidence. This study aimed to assess the effect of different INSTIs on body weight in HIV/AIDS patients.Methods: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database, and Wanfang databases were searched by computer to screen the relevant literature on INSTI treatment of HIV/AIDS patients, extract the data on weight changes in the literature, and perform network meta-analysis using Stata16.0 software.Results: Eight articles reported weight changes in HIV/AIDS patients, and weight gain was higher after treatment with dolutegravir (DTG) than with elvitegravir (EVG) in HIV/AIDS patients, and the difference was statistically significant [MD = 1.13, (0.18, 2.07)]. The network meta-analysis's consistency test results showed no overall and local inconsistency, and there was no significant difference in the results of the direct and indirect comparison (P > 0.05). The rank order of probability was DTG (79.2%) > Bictegravir (BIC) (77.9%) > Raltegravir (RAL) (33.2%) > EVG (9.7%), suggesting that DTG may be the INSTI drug that causes the most significant weight gain in HIV/AIDS patients.Conclusion: According to the literature data analysis, among the existing INSTIs, DTG may be the drug that causes the highest weight gain in HIV/AIDS patients, followed by BIC.

Download Full-text

Weight changes during chemotherapy for breast cancer

Sao Paulo Medical Journal ◽

10.1590/s1516-31802002000400005 ◽

2002 ◽

Vol 120 (4) ◽

pp. 113-117 ◽

Cited By ~ 25

Author(s):

Luciano José Megale Costa ◽

Paulo César Spotti Varella ◽

Auro del Giglio

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Body Weight ◽

Weight Gain ◽

Weight Change ◽

Prognostic Significance ◽

Disease Free Survival ◽

Weight Changes ◽

Free Survival ◽

Disease Free

CONTEXT: Patients receiving adjuvant chemotherapy for breast cancer have a tendency to gain weight. This tendency has determining factors not completely defined and an unknown prognostic impact. OBJECTIVE: To evaluate weight change during chemotherapy for breast cancer in a defined population and to identify its predisposing factors and possible prognostic significance. DESIGN: Observational, retrospective cohort study. SETTING: Private clinical oncology service. PARTICIPANTS: 106 consecutive patients with breast cancer treated between June 1994 and April 2000, who received neoadjuvant (n = 8), adjuvant (n = 74) or palliative (n = 24) chemotherapy. INTERVETION: Review of medical records and gathering of clinical information, including patients’ body weights before treatment and at follow-up reviews. MAIN MEASUREMENTS: Body weight change, expressed as percentage of body weight per month in treatment; role of clinical data in weight change; and influence of weight change in overall survival and disease-free survival. RESULTS: There was a mean increase of 0.50 ± 1.42% (p = 0.21) of body weight per month of treatment. We noted a negative correlation between metastatic disease and weight gain (r = -0.447, p < 0.0001). In the adjuvant and neoadjuvant therapy groups there was a mean weight gain of 0.91 ± 1.19 % (p < 0.00001) per month, whereas in the metastatic (palliative) group, we observed a mean loss of 0.52 ± 1.21% (p = 0.11) of body weight per month during the treatment. We did not observe any statistically significant correlation between weight changes and disease-free survival or overall survival. CONCLUSIONS: Women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy gain weight, whereas metastatic cancer patients will probably lose weight during palliative chemotherapy. Further studies are needed in order to evaluate the prognostic significance of weight changes during chemotherapy.

Download Full-text

Relations of body weight status in early adulthood and weight changes until middle age with metabolic syndrome in the Chinese population

International Journal of Community Medicine and Public Health ◽

10.18203/2394-6040.ijcmph20174810 ◽

2017 ◽

Vol 4 (11) ◽

pp. 4011

Author(s):

Liancheng Zhao ◽

Huanhuan Liu ◽

Long Zhou ◽

Ying Li ◽

Min Guo ◽

...

Keyword(s):

Metabolic Syndrome ◽

Body Weight ◽

Weight Gain ◽

Weight Change ◽

Chinese Population ◽

Weight Status ◽

Early Adulthood ◽

Weight Changes ◽

Body Weight Status ◽

Increased Risk

Background: The evidences for the relationship between long-term weight gain and metabolic syndrome (MetS) in Chinese population were limited. Therefore, this study aims to explore the association of body weight status in early adulthood and weight changes with MetS.Methods: Data from China Multicenter Collaborative Study of Cardiovascular Epidemiology including 12808 participants aged 35–59 were used. Participants were surveyed for cardiovascular risk factors and a self-reported weight at age 25, which was defined as early adulthood. Weight change was calculated as the difference between baseline weight and early adulthood weight. MetS was defined according to AHA/NHLBI definition in 2009. Multivariate logistic regression model was used to examine the association between early adulthood weight status, weight change and MetS.Results: Mean age of participants was 46.7 years, including 6134 men and 6674 women. The overall prevalence of MetS was 21.8%. After adjusted for age, sex and other confounding factors, both BMI at 25 age and weight gain were positively associated with the risk of MetS. Being overweight (BMI, 24–27.9 kg m-2) or obese (BMI ≥28 kg m-2) at early adulthood was related to an increased risk of MetS, the odds ratio (OR) and 95%confidence interval (CI) was 3.24 (2.82–3.72) and 13.31 (8.72–20.31). In addition, weight gain was also associated with higher risk of MetS (P for trend<0.01).Conclusions: Overweight and obesity in early adulthood and weight gain were both independently related to an increased risk of MetS in the middle-aged Chinese men and women.

Download Full-text

REPORTED WEIGHT CHANGE IN OLDER ADULTS AND PRESENCE OF FRAILTY

Journal of Frailty & Aging ◽

10.14283/jfa.2019.44 ◽

2019 ◽

pp. 1-8

Author(s):

R.S. Crow ◽

C.L. Petersen ◽

S.B. Cook ◽

C.J. Stevens ◽

A.J. Titus ◽

...

Keyword(s):

Older Adults ◽

Weight Loss ◽

Weight Gain ◽

Weight Change ◽

Primary Outcome ◽

Weight Changes ◽

Health And Nutrition ◽

The Impact ◽

Current Weight ◽

Time Point

Objective: A 5% change in weight is a significant predictor for frailty and obesity. We ascertained how self-reported weight change over the lifespan impacts rates of frailty in older adults. Methods: We identified 4,984 subjects ≥60 years with body composition measures from the National Health and Nutrition Examination Survey. An adapted version of Fried’s frailty criteria was used as the primary outcome. Self-reported weight was assessed at time current,1 and 10 years earlier and at age 25. Weight changes between each time point were categorized as ≥ 5%, ≤5% or neutral. Logistic regression assessed the impact of weight change on the outcome of frailty. Results: Among 4,984 participants, 56.5% were female, mean age was 71.1 years, and mean BMI was 28.2kg/m2. A weight loss of ≥ 5% had a higher association with frailty compared to current weight, age 25 (OR 2.94 [1.72,5.02]), 10 years ago (OR 1.68 [1.05,2.69]), and 1 year ago (OR 1.55 [1.02,2.36]). Weight gain in the last year was associated with increased rate of frailty (1.59 [1.09,2.32]). Conclusion: There is an association between frailty and reported weight loss over time while only weight gain in the last year has an association with frailty.

Download Full-text

Changes and variations of body weight as risk factors for coronary heart disease

Medicinski pregled ◽

10.2298/mpns0806274j ◽

2008 ◽

Vol 61 (5-6) ◽

pp. 274-280 ◽

Cited By ~ 1

Author(s):

Dragana Jovanovic ◽

Branko Jakovljevic ◽

Katarina Paunovic ◽

Dusan Grubor ◽

Aleksandar Milovanovic

Keyword(s):

Risk Factors ◽

Blood Pressure ◽

Coronary Heart Disease ◽

Weight Loss ◽

Body Weight ◽

Heart Disease ◽

Weight Gain ◽

Weight Change ◽

Healthy Controls ◽

Weight Changes

Introduction Weight variations are a common phenomenon. Therefore, concern has been raised about the association between weight changes and weight variations and coronary heart disease (CHD). The aim of this study was to estimate the influence of weight change and weight variations as risk factors for coronary heart disease. Materials and methods The investigation was conducted as an observational cross-sectional study, including 102 participants of both genders: 61 patients with CHD and 41 healthy controls. All participants underwent anthropometric measurements and completed a questionnaire that included 1) weight changes in adulthood (maximum and minimum weight), 2) presence and number of weight variations in the 10 years prior to the onset of disease and 3) the size of weight change (weight gain or weight loss in kg). One weight variation was defined as weight loss followed by weight gain for more than 10% of body weight, or about 7 kg. Multivariant logistic regression was used for the estimation of significant predictors for the occurrence of coronary heart disease. Results Participants with CHD had higher values of body weight in adulthood compared to healthy controls, larger number of weight variations in the last 10 years, and more frequently reported weight gain and weight loss for more than 10 kg. The highest risk for the occurrence of coronary heart disease was observed for participants who had more than 3 weight variations for 10% (OR=2.13; 95%CI=0.98-5.48), those with weight loss over 10 kg (OR=2.16; 95%CI=1.71-2.72) and those with weight gain over 10 kg (OR=2.71; 95%CI=1.08-6.83), regardless of gender, age, smoking, body mass index and blood pressure. Discussion Several mechanisms are suggested to explain the relationship between weight changes and variations and coronary heart disease, including changes in plasma lipid levels, insulin levels, decrease of HDL cholesterol, increase of C-reactive protein and increase of blood pressure. Conclusion This study suggests that frequent and very intense weight changes can be considered important predictors for the occurrence of coronary heart disease.

Download Full-text

The Relationship between Body Weight Change and Body Constitutions of Traditional Chinese Medicine in Patients with Schizophrenia

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2016/9585968 ◽

2016 ◽

Vol 2016 ◽

pp. 1-9 ◽

Cited By ~ 1

Author(s):

Jui-Fen Cheng ◽

Xuan-Yi Huang ◽

Te-Le Liu ◽

Ruey-Yun Wang ◽

Han-Yi Ching

Keyword(s):

Body Weight ◽

Weight Gain ◽

Waist Circumference ◽

Health Care Providers ◽

Weight Change ◽

The Body ◽

Care Providers ◽

Body Constitution ◽

Significant Difference ◽

The Relationship

Objective. To explore the relationship between body constitution (BC) types and weight change in patients with schizophrenia and who underwent second-generation antipsychotics (SGAs) treatment.Method. Body weight and waist circumference of eighty-five participants were measured for 6 consecutive weeks. Constitutions of Yin-Xu, Yang-Xu, and Stasis were assessed using the Body Constitution Questionnaire (BCQ).Results. Participants with body constitutions Yin-Xu (50.6%), Yang-Xu (49.4%), or Stasis (38.8%) exhibited worse physical condition and unhealthy daily habits, particularly in Stasis constitution. Moreover, Stasis constitution was significantly associated with several factors, including BMI, body weight, waist circumference, perception of stress, perception of health, staying up late, and less physical exercise. However, perception of stress showed significant difference in Yin-Xu, Yang-Xu, and Stasis. Generalized estimating equation (GEE) analysis revealed that significant time effects in body weight increase in the imbalanced BC types and gentleness BC type. SGAs induced weight gain in imbalanced BC type as well as gentleness BC type, especially treated with olanzapine.Conclusions. This is the first study to explore the longitudinal relationship between BC and weight gain in schizophrenia patients undergoing SGAs treatment. Health care providers should focus on weight gain problems in schizophrenia patients who underwent SGAs treatment.

Download Full-text

Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases

Nutrients ◽

10.3390/nu11020303 ◽

2019 ◽

Vol 11 (2) ◽

pp. 303 ◽

Cited By ~ 1

Author(s):

Rocco Spagnuolo ◽

Tiziana Montalcini ◽

Daniele De Bonis ◽

Yvelise Ferro ◽

Cristina Cosco ◽

...

Keyword(s):

Body Weight ◽

Weight Gain ◽

Inflammatory Bowel Diseases ◽

Weight Change ◽

Transient Elastography ◽

Liver Steatosis ◽

Significant Difference ◽

Bowel Diseases ◽

Inflammatory Bowel

Background and Aim: Most studies focused on the benefits of weight loss on hepatic steatosis and no studies have been specifically designed to assess the role of weight gain on the development of liver steatosis in patients affected by inflammatory bowel diseases. The aim of this study was to analyse the relation between weight change over time and liver steatosis in patients with inflammatory bowel diseases. Methods: We retrospectively evaluated a population of 89 ambulatory patients in clinical remission or affected by mild disease, as determined from disease activity indices, with at least one follow-up visit. Transient elastography was used to quantify liver steatosis. Results: A total of 49 individuals (55%) were overweight/obese at baseline. A significant difference in weight change was found between participants that improved, were stable and worsened, over a mean follow-up of four years. (−1.0 kg ± 4; 2.5 kg ± 6; and 5.4 kg ± 5; respectively, p = 0.009). We found a greater probability of worsening in the hepatic fat content in individuals who gained more than 6% of body weight than in those gaining less than this value (log–rank (Mantel–Cox) χ2 test = 9.85; df = 1; p = 0.002). Conclusions: A body weight gain of 6% increases the probability of deterioration in liver steatosis over a period of four years in patients with inflammatory bowel diseases. Weight gain prevention with lifestyle interventions may be the cornerstone treatment of these patients.

Download Full-text

SAT-436 Long-Term Analysis of Weight Change Following Thyroidectomy

Journal of the Endocrine Society ◽

10.1210/jendso/bvaa046.1963 ◽

2020 ◽

Vol 4 (Supplement_1) ◽

Author(s):

Reece Moore ◽

Parker McDuffie ◽

Keri Broadley ◽

Denise Carneiro-Pla ◽

Mahsa Javid

Keyword(s):

Weight Gain ◽

Weight Change ◽

Weight Increase ◽

Common Source ◽

Weight Changes ◽

Thyroid Cancer Patient ◽

Significant Difference ◽

Post Operation

Abstract Introduction: Weight gain is a common source of apprehension for patients undergoing thyroidectomy. However, contradictory reports exist regarding the presence and degree of weight gain following thyroid surgery and all known studies have short term follow-up This study evaluated weight changes following total thyroidectomy (TT) and lobectomy (L) over an extended time period. Methods: Retrospective analysis was performed of weight changes following surgery for patients who underwent TT or L (n=387) as compared with those undergoing parathyroidectomy for primary hyperparathyroidism (n=201) in a tertiary referral hospital between 2007-2012. Clinical, demographic and pre- and postoperative weight data was collected with a median follow-up of 55.6 months. Results: Postoperative weight change was observed at 1, 6, 12, and 36-months in patients who underwent TT (μ=+0.21kg, μ=+1.33kg, μ=+0.59kg, μ=+0.60kg; p<0.05) and at 6-months for patients who underwent L (μ=+0.93kg, p<0.05) compared with those who underwent parathyroidectomy. Patients having TT and L showed a general trend of weight gain compared to the control group up to 108-months post-operation; however, this weight gain was non-significant (p<0.05). Significant postoperative weight gain was observed in patients who had TT (1-month μ=+0.40kg, 6-months μ=+2.14kg, and 12-months μ=+1.40kg) and L (6-months μ=+1.04kg) for benign conditions compared with the parathyroidectomy group. Patients who had TT gained 0.40kg more than L patients at 12-months post-op (p<0.05), but no significant difference existed at other time points up to 108-months. Tukey HSD post-hoc analysis showed weight gain in benign, thyroiditis, and thyroid cancer patient groups was not significantly different from 6-months to 108-months post-operation. Furthermore, neither race nor sex was correlated with weight gain. Relative risks with 95% CI for weight gain following TT and L compared to control are: 1-month TT=1.74, 0.96-3.14, L=1.59, 0.58-2.58; 6-month TT=1.27, 0.85-1.89, L=1.42, 0.85-2.11; 12-month TT=1.44, 0.92-2.28, L=1.34, 0.86-2.36; 24-month TT=1.17, 0.82-1.67, L=1.22, 0.69-1.60. In the group of patients who gained greater than 2kg, those who underwent TT had significant weight increase compared to the parathyroidectomy group at 6-months postoperatively (Mann-Whitney U, p=0.011). In the subgroup of patients with weight gain greater than 2kg, those who had L did not have significant weight increase at any time point. Conclusion: Weight change following TT when compared with parathyroidectomy is significant shortly after surgery. However, these changes are not significant at long-term follow-up.

Download Full-text

Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis

PLoS ONE ◽

10.1371/journal.pone.0244944 ◽

2021 ◽

Vol 16 (2) ◽

pp. e0244944

Author(s):

Maarten Bak ◽

Marjan Drukker ◽

Shauna Cortenraad ◽

Emma Vandenberk ◽

Sinan Guloksuz

Keyword(s):

Body Weight ◽

Weight Gain ◽

Weight Change ◽

Psychiatric Diagnosis ◽

Body Weight Gain ◽

Meta Analysis ◽

Bodyweight Gain ◽

Body Weight Change ◽

Meta Analyses ◽

The Impact

Introduction Antipsychotics are associated with bodyweight gain and metabolic disturbance. Previous meta-analyses were limited to mainly antipsychotic switch studies in patients with a diagnosis of schizophrenia or psychosis with short follow-up periods. The present meta-analysis aimed to analyse the impact of weight change in antipsychotic-naive and antipsychotics switch patients and whether body weight change depended on diagnosis. Method We performed a meta-analysis of clinical trials of antipsychotics that reported weight change, irrespective of psychiatric diagnosis. Outcome measure was body weight change. Studies were classified into antipsychotic-naive and antipsychotic-switch. Forest plots stratified by antipsychotic and the duration of antipsychotic use were generated and results were summarised in figures. Results In total, 404 articles were included for the quantitative synthesis. 58 articles were on antipsychotic naive patients. In the antipsychotic naive group, all antipsychotics resulted in body weight gain. In the antipsychotic switch group, most antipsychotics likewise resulted in bodyweight gain, with exception of amisulpride, aripiprazole and ziprasidone that showed no body weight gain or even some weight loss after switching antipsychotics. Diagnosis was not a discriminating factor of antipsychotic induced weight change. Conclusion Antipsychotic use resulted in substantial increase in body weight in antipsychotic-naive patients. In antipsychotic-switch patients the weight gain was mild and not present in amisulpride, aripiprazole and ziprasidone. In both groups, weight gain was irrespective of the psychiatric diagnosis.

Download Full-text

Serum molecular signatures of weight change during early breast cancer chemotherapy

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e11534 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e11534-e11534

Author(s):

J. Stebbing ◽

H. C. Keun ◽

J. Sidhu ◽

M. Patterson ◽

S. R. Bloom ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Weight Gain ◽

Early Breast Cancer ◽

Body Fat ◽

Weight Change ◽

Peptide Yy ◽

Resonance Spectroscopy ◽

Weight Changes ◽

Tnf Α

e11534 Background: Weight gain in women receiving chemotherapy following breast cancer diagnosis has negative implications on quality of life and those who gain weight during treatment appear to be at higher risk of disease recurrence. The mechanism(s) implicated in chemotherapy associated weight gain are poorly understood. Methods: To investigate this further, we assessed the metabolic, cytokine and appetite related peptide alterations before and during adjuvant FEC chemotherapy for early breast cancer in post-menopausal women, and correlated these with body mass measurements. Specifically, we performed global metabolic profiling (metabonomics/ metabolomics) using 1H nuclear magnetic resonance spectroscopy of sequential sera, examined ghrelin immunoreactivity, performed radioimmunoassays for glucagon like peptide-1 (GLP-1) and peptide YY (PYY) and electro-chemiluminescent cytokine analyses (tumor necrosis factor-α and interleukin-6; TNF-α, IL-6) on the sequential samples. Results: In those who gained ≥ 1.5kg (on average ∼5% of initial body weight), several metabolite levels were positively associated with weight change, in particular lactate which was 55% greater in patients with increased body weight during chemotherapy compared to those with stable weight during chemotherapy (p<0.01; the pre-specified primary end-point). A significant inverse relationship was also observed between levels of TNF-α and weight change group (ρ 0.476, p<0.05). Baseline lactate, alanine and body fat were all prognostic for weight gain (ROC AUC >0.77, p<0.05). No significant associations were observed between any other parameter and weight gain, nor any parameter and tumor burden, including cytokine and appetite peptide alterations. Conclusions: Metabonomics identifies pathways perturbed during early chemotherapy for breast cancer, and establishes a positive association between serum lactate, body fat, TNF-α and substantive weight changes during chemotherapy. Interventions that target these processes may be clinically useful in breast cancer. No significant financial relationships to disclose.

Download Full-text